Ticker

Minerva Neurosciences, Inc (NASDAQ: NERV - Get Free Report) was the recipient of a large growth in short interest in March. As of March 31st, there was short interest totaling 1,020,925 shares, a growth of 82.5% from the March 15th total of 559,530 shares. Currently, 2.6% of the shares of the stock are short sold. Based

BURLINGTON, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced a leadership transition with the appointment of Jim O'Connor as Chief Business Officer (CBO), effective April 21, 2026, as Geoff Race, the Company's President, has elected to…

Roluperidone has been de-risked by consistent positive results in two prior pivotal trials and remains the only late-stage drug candidate for this high-need population Efficacy topline data expected 2H 2027 BURLINGTON, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system…

Trial demonstrated no safety concerns when co-administering roluperidone and olanzapine The Company continues to advance the program, with the confirmatory Phase 3 trial now enrolling and topline data anticipated in the second half of 2027 BURLINGTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of…

Minerva Neurosciences (NASDAQ: NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of schizophrenia-an area where management has historically lagged behind treatments for positive symptoms. Company focus: negative symptoms and unmet need In the presentation, Minerva's team emphasized that schizophrenia